Table 8.

Deterministic sensitivity analyses of parameters that have a large effect on the model results

	Total hip replacement				Total knee replacement
	Incremental events	Incremental costs (hospital)	Incremental costs (SHI)	ICER (SHI)	Incremental events	Incremental costs (hospital)	Incremental costs (SHI)	ICER (SHI)
Base case	0.0070	31.8	18.0	2,569.3	0.0203	20.7	−27.2	dominance
Probability that a VTE event is a DVT during prophylaxis with enoxaparin (Parameter 4)
0.90 0.95 0.99	0.00850.00730.0064	31.431.732.0	15.017.419.3	1,762.72,364.33,006.6	0.03220.02440.0181	6.215.723.4	−49.9−35.0−23.0	dominancedominance dominance
Probability that a DVT is symptomatic during prophylaxis with enoxaparin (Parameter 6)
0.090.170.26	0.00490.00710.0095	32.631.830.9	21.017.914.5	4,244.12,523.91,521.3	0.01470.02860.0443	24.215.55.8	−21.8−35.3−50.4	dominance dominance dominance
Probability that an asymptomatic DVT becomes symptomatic (Parameter 7)
0.010.150.60	0.00270.00590.0160	31.831.831.8	26.320.20.7	9,570.33,428.341.9	0.01750.02790.0613	20.720.720.7	−21.4−42.893.2	dominance dominance 1520.0
Probability that a DVT is symptomatic during prophylaxis with rivaroxaban (Parameter 12)
0.060.160.50	0.00820.00760.0055	31.431.632.4	16.517.320.0	2,026.22,291.63,626.0	0.11230.10320.0723	18.524.143.0	−30.6−21.88.2	dominance dominance 113.3
Prophylaxis costs with enoxaparin in the case of post-discharge VTE or no VTE and no ME (Parameter 14)
20% lower20% higher	0.00700.0070	31.8 31.8	39.2−3.2	5,592.5dominance	0.0203 0.0203	20.7 20.7	−26.9−27.5	dominance dominance
Prophylaxis costs with rivaroxaban in the case of post-discharge VTE or no VTE and no ME (Parameter 17)
20% lower20% higher	0.00700.0070	25.438.3	−8.944.9	dominance6,402.5	0.02030.0203	14.227.2	−27.6−26.8	dominance dominance